New research shows 92% of cancer patients stayed cancer-free for two years after immune-based therapy, potentially avoiding ...

According to the results of the early study, published simultaneously in the New England Journal of Medicine, 92% of patients ...

Adding pembrolizumab (Keytruda), before and after surgery, to standard adjuvant therapy for locally advanced head and neck ...

Immunotherapy let some cancer patients with mismatch repair deficient tumors completely avoid surgery, chemo and radiation, a ...

For a limited group of cancer patients who have solid tumors in the stomach, rectum, esophagus and other organs, an ...

The AACR meeting was full of promising data on the vaccine against cervical cancer, a lung cancer drug and the next ...

The session follows the American Association for Cancer Research's prior call to action against executive orders that would ...

We are navigating political interference, institutional instability, and growing uncertainty across the cancer research ...

The addition of neoadjuvant and adjuvant pembrolizumab to standard of care significantly improved outcomes for certain ...

Ending a 20-year-plus drought, Merck & Co.’s Keytruda demonstrated that its use around surgery can reduce the risk of certain ...

Summary: Myriad's Precise MRD test is an ultrasensitive second-generation hybrid-capture-based tumor-informed assay that ...